Table 3.
Baseline patient characteristicsa
| Study | Vasoconstrictor | Age (y) | Serum concentrationb | MAP (mm Hg) | ||
|---|---|---|---|---|---|---|
| Randomized | Creatinine | Bilirubin | Albumin | |||
| Alessandria et al., 2007 [18]c | terlipressin | 55.0 (6.9) | 2.5 (1.0) | 5.1 (3.5) | 3.0 (0.3) | 74.0 (10.4) |
| noradrenaline | 56.0 (9.5) | 2.3 (0.6) | 4.1 (3.2) | 3.0 (0.6) | 71.0 (6.3) | |
| Martín-Llahí et al., 2008 [19]c | terlipressin | 59.0 (10.0) | 3.6 (1.5) | 18.1 (19.1) | 3.0 (0.7) | 73.0 (10.0) |
| Neri et al., 2008 [20] | terlipressin | 59.0 (4.0) | 2.8 (1.1) | — | 2.7 (0.3) | 82.0 (2.0) |
| Sanyal et al., 2008 [21] | terlipressin | 50.6 (10.5) | 4.0 (2.2) | 15.0 (13.6) | 2.6 (0.8) | 75.5 (11.4) |
| Sharma et al., 2008 [22] | terlipressin | 47.8 (9.8) | 3.0 (0.5) | 7.6 (9.8) | 2.6 (0.6) | 81.4 (11.4) |
| noradrenaline | 48.2 (13.4) | 3.3 (1.3) | 5.2 (6.8) | 2.4 (0.4) | 78.2 (5.3) | |
| Silawat et al., 2011 [27] | terlipressin | — | 3.0 (1.3) | 3.4 (2.1) | 2.4 (0.7) | 67.6 (16.4) |
| Singh et al., 2012 [29] | terlipressin | 51.4 (11.6) | 3.3 (0.7) | 4.0 (2.6) | 2.8 (0.4) | 64.7 (11.9) |
| noradrenaline | 48.3 (11.6) | 3.1 (0.7) | 4.7 (5.7) | 2.8 (0.2) | 65.2 (10.2) | |
| Tavakkoli et al., 2012 [30]c | midodrine/octreotide | 52.9 (12.6) | 2.6 (0.8) | 11.6 (12.2) | 2.6 (0.3) | 69.8 (7.1) |
| noradrenaline | 52.0 (12.9) | 2.6 (0.7) | 8.0 (7.8) | 2.7 (0.2) | 73.4 (6.7) | |
| Prospective | ||||||
| Angeli et al., 1999 [13] | midodrine/octreotide | 62.0 (6.7) | 5.0 (2.0) | 4.3 (2.9) | 3.0 (0.2) | 75.9 (6.7) |
| Uriz et al., 2000 [14]c | terlipressin | 54.0 (11.0) | 3.9 (2.1) | 14.0 (18.0) | 3.2 (0.6) | 68.0 (6.0) |
| Mulkay et al., 2001 [15] | terlipressin | 53.5 (5.1) | 3.4 (0.5) | 6.2 (6.3) | 2.9 (0.3) | 76.0 (5.0) |
| Wong et al., 2004 [17] | midodrine/octreotide | 55.2 (7.9) | 2.9 (1.2) | 3.0 (1.6) | 3.2 (1.0) | 80.6 (14.7) |
| Muñoz et al., 2009 [23] | terlipressin | 54.2 (21.5) | 3.3 (5.9) | — | — | 69.6 (29.6) |
| Rivero et al., 2010 [26] | terlipressin | — | — | — | — | — |
| Salerno et al., 2011 [1] | terlipressin | 62.0 (7.6) | 3.2 (1.2) | 15.1 (10.1) | 2.8 (0.4) | 80.4 (8.2) |
| midodrine/octreotide | 62.0 (5.9) | 3.2 (0.9) | 15.1 (7.8) | 2.8 (0.3) | 80.4 (6.4) | |
| Narahara et al., 2012 [28] | terlipressin | 59.1 (11.8) | 3.0 (0.8) | 9.4 (7.6) | 2.5 (0.4) | 74.0 (14.0) |
| Retrospective | ||||||
| Moreau et al., 2002 [16] | terlipressin | 56.0 (10.0) | 2.9 (1.1) | 11.8 (12.9) | 2.8 (0.7) | 78.0 (20.0) |
| Skagen et al., 2009 [24] | midodrine/octreotide | 52.7 (10.6) | 2.5 (1.3) | — | — | — |
| von Kalckreuth et al., 2009 [25] | terlipressin | 51.8 (9.4) | — | — | — | — |
aIndicated values are mean (standard deviation).
bSerum creatinine and serum bilirubin in mg/dL and serum albumin in g/dL.
cIndicated baseline data reported only in the aggregate for types 1 and 2 HRS. However, outcome data (HRS reversal/survival) were reported separately for patients with type 1HRS, and only those separate outcome data for type 1 HRS were used in the meta-analysis.
Abbreviation: HRS, hepatorenal syndrome; MAP, mean arterial pressure.